BRPI0917119A2 - composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. - Google Patents

composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.

Info

Publication number: BRPI0917119A2
Authority: BR; Brazil
Prior art keywords: compound; adp; ribose; polymerase; disease
Prior art date: 2008-08-06

Application number

BRPI0917119A

Other languages

English (en)

Inventor

Bing Wang

Daniel Chu

Original Assignee

Biomarin Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-06

Filing date

2009-07-27

Publication date

2015-11-17

2009-07-27 Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc

2015-11-17 Publication of BRPI0917119A2 publication Critical patent/BRPI0917119A2/pt

2021-07-13 Publication of BRPI0917119B1 publication Critical patent/BRPI0917119B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Inorganic Chemistry (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Obesity (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)

BRPI0917119-3A 2008-08-06 2009-07-27 Composto, composição farmacêutica, uso dos mesmos e seu processo de fabricação BRPI0917119B1 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US8668708P	2008-08-06	2008-08-06
US61/086,687		2008-08-06
US15103609P	2009-02-09	2009-02-09
US61/151,036		2009-02-09
US17308809P	2009-04-27	2009-04-27
US61/173,088		2009-04-27
PCT/US2009/051879 WO2010017055A2 (en)	2008-08-06	2009-07-27	Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)

Publications (2)

Publication Number	Publication Date
BRPI0917119A2 true BRPI0917119A2 (pt)	2015-11-17
BRPI0917119B1 BRPI0917119B1 (pt)	2021-07-13

Family

ID=41129519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0917119-3A BRPI0917119B1 (pt)	2008-08-06	2009-07-27	Composto, composição farmacêutica, uso dos mesmos e seu processo de fabricação

Country Status (32)

Country	Link
US (7)	US8012976B2 (pt)
EP (3)	EP2326650B9 (pt)
JP (3)	JP5984389B2 (pt)
KR (1)	KR101846029B1 (pt)
CN (3)	CN103896942A (pt)
AR (1)	AR072970A1 (pt)
AU (1)	AU2009279944B2 (pt)
BR (1)	BRPI0917119B1 (pt)
CA (1)	CA2732797C (pt)
CY (3)	CY1115022T1 (pt)
DK (2)	DK2767537T3 (pt)
ES (2)	ES2625817T3 (pt)
FR (1)	FR19C1071I2 (pt)
GB (1)	GB2462361A (pt)
HK (2)	HK1157755A1 (pt)
HR (1)	HRP20170982T1 (pt)
HU (2)	HUE035295T2 (pt)
IL (1)	IL211070A (pt)
LT (2)	LT2767537T (pt)
LU (1)	LUC00140I2 (pt)
MX (1)	MX2011001328A (pt)
NL (1)	NL301021I2 (pt)
NO (1)	NO2019042I1 (pt)
NZ (1)	NZ591166A (pt)
PL (2)	PL2767537T3 (pt)
PT (2)	PT2326650E (pt)
SG (2)	SG10201809895YA (pt)
SI (2)	SI2767537T1 (pt)
SM (1)	SMT201700312T1 (pt)
TW (2)	TW201422617A (pt)
WO (1)	WO2010017055A2 (pt)
ZA (1)	ZA201100897B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101846029B1 (ko)	2008-08-06	2018-04-06	메디베이션 테크놀로지즈 엘엘씨	폴리(ａｄｐ-리보오스)폴리머라아제 (ｐａｒｐ)의 디히드로피리도프탈라지논 억제제
RU2016141566A (ru)	2008-12-19	2018-12-20	Вертекс Фармасьютикалз Инкорпорейтед	Производные пиразина, используемые в качестве ингибиторов киназы atr
CN106943406A (zh)	2010-02-03	2017-07-14	麦迪韦逊科技有限公司	用于pten基因缺失相关疾病的治疗的聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) *	2010-02-04	2011-08-04	Daniel Chu	5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
ES2606174T3 (es) *	2010-02-08	2017-03-23	Medivation Technologies, Inc.	Procesos de síntesis de derivados de dihidropiridoftalazinona
WO2011130661A1 (en) *	2010-04-16	2011-10-20	Biomarin Pharmaceutical Inc.	Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
EP2569313A1 (en)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
SG10201710578TA (en) *	2010-10-21	2018-02-27	Medivation Technologies Inc	Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012166151A1 (en) *	2011-06-03	2012-12-06	Biomarin Pharmaceutical Inc.	Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) *	2011-08-19	2013-02-28	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
EP3733185B1 (en)	2011-09-30	2022-12-07	Vertex Pharmaceuticals Incorporated	Treating non-small cell lung cancer with atr inhibitors
CN106496173A (zh) *	2011-09-30	2017-03-15	沃泰克斯药物股份有限公司	用于制备可用作atr激酶抑制剂的化合物的方法
KR101684039B1 (ko) *	2011-12-31	2016-12-07	베이진 엘티디	Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논
ME02855B (me)	2011-12-31	2018-04-20	Beigene Ltd	KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI
SG11201404216TA (en)	2012-01-20	2014-08-28	Dennis Brown	Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
DK2833973T3 (en)	2012-04-05	2018-01-02	Vertex Pharma	Compounds useful as ATR kinase inhibitors and combination therapies thereof
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
JP6223995B2 (ja)	2012-11-08	2017-11-01	日本化薬株式会社	カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
WO2014164767A1 (en)	2013-03-13	2014-10-09	Forma Therapeutics, Inc.	Novel compounds and compositions for inhibition of fasn
US9993460B2 (en)	2013-07-26	2018-06-12	Race Oncology Ltd.	Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
WO2015069851A1 (en)	2013-11-07	2015-05-14	Biomarin Pharmaceutical Inc.	Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
CN103772395B (zh) *	2014-01-23	2016-05-11	中国药科大学	一类具有parp抑制活性的化合物、其制备方法及用途
JP6783224B2 (ja)	2014-04-04	2020-11-11	デルマーファーマシューティカルズ	肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
US11179394B2 (en)	2014-06-17	2021-11-23	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of Chk1 and ATR inhibitors
EA201790290A1 (ru)	2014-07-31	2017-07-31	Медивэйшн Текнолоджиз, Инк.	Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
CA2977685C (en)	2015-03-02	2024-02-20	Sinai Health System	Homologous recombination factors
US9957267B2 (en)	2015-07-01	2018-05-01	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
CA2994895A1 (en)	2015-08-25	2017-03-02	Beigene, Ltd.	Process for preparing parp inhibitor, crystalline forms, and uses thereof
WO2017059357A1 (en)	2015-09-30	2017-04-06	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US9708319B1 (en) *	2016-06-13	2017-07-18	Yong Xu	Synthesis of PARP inhibitor talazoparib
EP3519051B1 (en) *	2016-09-27	2021-09-22	Beigene, Ltd.	Treatment of cancers using combination comprising parp inhibitors
JP6541635B2 (ja) *	2016-10-28	2019-07-10	ベイジーンリミテッド	Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) *	2016-12-16	2018-06-29	中国科学院上海药物研究所	一种Talazoparib药物组合物及其应用
CN107556312B (zh) *	2016-12-29	2020-04-10	广州丹康医药生物有限公司	具有parp抑制活性的新型稠环化合物、其制备方法和用途
WO2018122168A1 (en)	2016-12-29	2018-07-05	Bayer Pharma Aktiengesellschaft	Combinations of bub1 kinase and parp inhibitors
CN107573341B (zh) *	2016-12-29	2020-08-14	广州丹康医药生物有限公司	作为parp抑制剂的新型稠环化合物、其制备方法和应用
CN110392687B (zh)	2017-02-28	2022-08-02	百济神州(苏州)生物科技有限公司	稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
WO2018205938A1 (zh) *	2017-05-08	2018-11-15	广州丹康医药生物有限公司	Parp抑制剂、其药物组合物、制备方法和应用
WO2019023278A1 (en)	2017-07-25	2019-01-31	Crinetics Pharmaceuticals, Inc.	MODULATORS OF SOMATOSTATIN AND USES THEREOF
EP3694551A1 (en)	2017-10-13	2020-08-19	Merck Patent GmbH	Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh)	2017-12-18	2019-10-01	美商輝瑞股份有限公司	治療癌症的方法及組合療法
CN110272419A (zh) *	2018-03-14	2019-09-24	上海艾力斯医药科技有限公司	二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) *	2018-04-28	2021-09-17	苏州莱克施德药业有限公司	一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
CN108676888B (zh) *	2018-07-12	2022-01-28	吉林大学	一种肺部恶性肿瘤易感性预测试剂盒及系统
TWI767148B (zh)	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)
EP3873214A4 (en)	2018-10-29	2022-07-13	Forma Therapeutics, Inc.	Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
EP3876940A1 (en)	2018-11-05	2021-09-15	Pfizer Inc.	Combinations for treating cancer
ES2966719T3 (es)	2019-05-14	2024-04-23	Suzhou Four Health Pharmaceuticals Co Ltd	Derivados de quinazolina-2,4-diona como inhibidores de PARP
MX2021013774A (es)	2019-05-14	2021-12-10	Nuvation Bio Inc	Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
WO2021097046A1 (en)	2019-11-13	2021-05-20	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
CN111116514B (zh) *	2020-01-10	2024-03-19	广州科锐特生物科技有限公司	一种1-环丙甲酰基哌嗪盐酸盐的制备方法
CA3174908A1 (en)	2020-03-09	2021-09-16	Pfizer Inc.	Fusion proteins and uses thereof
EP4243785A1 (en)	2020-11-13	2023-09-20	Pfizer Inc.	Talazoparib soft gelatin capsule dosage form
EP4256088A1 (en)	2020-12-07	2023-10-11	Pfizer Inc.	Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
TW202304928A (zh)	2021-03-23	2023-02-01	美商諾維雪碧歐公司	抗癌核荷爾蒙受體標靶化合物
WO2022200982A1 (en)	2021-03-24	2022-09-29	Pfizer Inc.	Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
US20240279225A1 (en) *	2021-04-08	2024-08-22	Board Of Regents, The University Of Texas System	Compounds and methods for theranostic targeting of parp activity
AU2022269568A1 (en)	2021-05-03	2023-11-16	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
EP4089093A1 (en) *	2021-05-12	2022-11-16	Eberhard Karls Universität Tübingen Medizinische Fakultät	Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en)	2022-01-08	2023-07-13	Pfizer Inc.	Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en)	2022-04-15	2023-10-19	Ideaya Biosciences, Inc.	Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en)	2022-06-01	2023-12-07	Ideaya Biosciences, Inc.	Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2023239789A1 (en) *	2022-06-08	2023-12-14	Valo Health, Inc.	Tricyclic phthalazinone parp inhibitors and methods of use
CN115572218B (zh) *	2022-08-29	2024-04-16	江阴勒森生物科技有限公司	一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
TW202425975A (zh)	2022-10-02	2024-07-01	美商輝瑞大藥廠	用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh)	2022-12-17	2024-07-01	美商輝瑞大藥廠	用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN116283924B (zh) *	2023-01-16	2024-07-26	四川效佳科技有限公司	一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US106631A (en) *		1870-08-23		Improvement in seed-planter
US4415504A (en)	1981-09-21	1983-11-15	Tanabe Seiyaku Co., Ltd.	p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja)	1982-06-21	1983-12-27	Nippon Shinyaku Co Ltd	２−キノロン誘導体
US5328905A (en) *	1987-07-20	1994-07-12	Duphar International Research B.V.	8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
DE69524182T3 (de)	1994-08-12	2009-07-09	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Nukleinsäuresonden umfassend ein Fragment des 17Q-verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
JP2002503943A (ja)	1994-08-12	2002-02-05	ミリアド・ジェネティックス・インコーポレイテッド	１７ｑ−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性
GB9505538D0 (en) *	1995-03-18	1995-05-03	Ciba Geigy Ag	New compounds
ID19155A (id)	1996-12-13	1998-06-18	Tanabe Seiyaku Co	Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de)	1997-06-27	1999-01-07	Hoechst Schering Agrevo Gmbh	3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en)	1997-09-03	2003-02-04	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en)	1997-12-03	2001-04-21	Dainippon Ink & Chemicals	Quinolinone derivative, method for preparing the same, and anti-allergic agent
JP2002515490A (ja)	1998-05-15	2002-05-28	ギルフォードファーマシューティカルズインコーポレイテッド	Ｐａｒｐ活性を抑制する縮合三環化合物
DE19921567A1 (de)	1999-05-11	2000-11-16	Basf Ag	Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) *	2000-04-18	2001-10-31	Meiji Seika Kaisha Ltd	三環性フタラジノン誘導体
JP2002284699A (ja)	2001-03-28	2002-10-03	Sumitomo Pharmaceut Co Ltd	視細胞変性疾患治療剤
AR036081A1 (es)	2001-06-07	2004-08-11	Smithkline Beecham Corp	Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv)	2001-06-28	2001-06-28	Astrazeneca Ab	Compounds
EP2281818A1 (en)	2002-02-19	2011-02-09	Ono Pharmaceutical Co., Ltd.	Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
EP1340819A1 (en)	2002-02-28	2003-09-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Microsatellite markers
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
EP1400244A1 (en) *	2002-09-17	2004-03-24	Warner-Lambert Company LLC	New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2004043959A1 (ja) *	2002-11-12	2004-05-27	Mochida Pharmaceutical Co., Ltd.	新規parp阻害剤
EP1633724B1 (en)	2003-03-12	2011-05-04	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
ES2396334T3 (es) *	2003-05-28	2013-02-20	Eisai Inc.	Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
TW200533664A (en)	2004-02-18	2005-10-16	Astrazeneca Ab	Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
GB0612971D0 (en)	2006-06-30	2006-08-09	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8198448B2 (en)	2006-07-14	2012-06-12	Amgen Inc.	Fused heterocyclic derivatives and methods of use
NZ581614A (en)	2007-05-03	2011-06-30	Pfizer Ltd	2-pyridine carboxamide derivatives as sodium channel modulators
EP2178875A1 (en)	2007-08-22	2010-04-28	4Sc Ag	Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
AU2008308664B2 (en) *	2007-10-03	2014-07-17	Eisai Inc.	PARP inhibitor compounds, compositions and methods of use
CN101998959B (zh)	2008-02-06	2013-08-28	生物马林药物股份有限公司	聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
KR101846029B1 (ko)	2008-08-06	2018-04-06	메디베이션 테크놀로지즈 엘엘씨	폴리(ａｄｐ-리보오스)폴리머라아제 (ｐａｒｐ)의 디히드로피리도프탈라지논 억제제
US20110301350A1 (en)	2008-08-12	2011-12-08	Boehringer Ingelheim International Gmbh	Process for preparing cycloalkyl-substituted piperazine compounds
CN106943406A (zh)	2010-02-03	2017-07-14	麦迪韦逊科技有限公司	用于pten基因缺失相关疾病的治疗的聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en)	2010-02-04	2011-08-04	Daniel Chu	5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
ES2606174T3 (es)	2010-02-08	2017-03-23	Medivation Technologies, Inc.	Procesos de síntesis de derivados de dihidropiridoftalazinona
WO2011130661A1 (en)	2010-04-16	2011-10-20	Biomarin Pharmaceutical Inc.	Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en)	2010-05-04	2011-11-10	Biomarin Pharmaceutical Inc.	Methods of using semi-synthetic glycopeptides as antibacterial agents
SG10201710578TA (en)	2010-10-21	2018-02-27	Medivation Technologies Inc	Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012166151A1 (en)	2011-06-03	2012-12-06	Biomarin Pharmaceutical Inc.	Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en)	2011-08-19	2013-02-28	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en)	2011-08-30	2013-02-28	Biomarin Pharmaceutical, Inc.	Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2015069851A1 (en)	2013-11-07	2015-05-14	Biomarin Pharmaceutical Inc.	Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (ru)	2014-07-31	2017-07-31	Медивэйшн Текнолоджиз, Инк.	Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

2009
- 2009-07-27 KR KR1020117005152A patent/KR101846029B1/ko active IP Right Grant
- 2009-07-27 PT PT98053606T patent/PT2326650E/pt unknown
- 2009-07-27 AU AU2009279944A patent/AU2009279944B2/en active Active
- 2009-07-27 HU HUE14154664A patent/HUE035295T2/en unknown
- 2009-07-27 EP EP09805360.6A patent/EP2326650B9/en active Active
- 2009-07-27 PL PL14154664T patent/PL2767537T3/pl unknown
- 2009-07-27 ES ES14154664.8T patent/ES2625817T3/es active Active
- 2009-07-27 CA CA2732797A patent/CA2732797C/en active Active
- 2009-07-27 JP JP2011522113A patent/JP5984389B2/ja active Active
- 2009-07-27 PT PT141546648T patent/PT2767537T/pt unknown
- 2009-07-27 BR BRPI0917119-3A patent/BRPI0917119B1/pt active IP Right Grant
- 2009-07-27 US US12/510,096 patent/US8012976B2/en active Active
- 2009-07-27 ES ES09805360.6T patent/ES2466565T3/es active Active
- 2009-07-27 LT LTEP14154664.8T patent/LT2767537T/lt unknown
- 2009-07-27 DK DK14154664.8T patent/DK2767537T3/da active
- 2009-07-27 SG SG10201809895YA patent/SG10201809895YA/en unknown
- 2009-07-27 NZ NZ591166A patent/NZ591166A/xx unknown
- 2009-07-27 CN CN201410003342.9A patent/CN103896942A/zh active Pending
- 2009-07-27 SI SI200931668T patent/SI2767537T1/sl unknown
- 2009-07-27 CN CN200980139634.2A patent/CN102171214B/zh active Active
- 2009-07-27 PL PL09805360T patent/PL2326650T3/pl unknown
- 2009-07-27 WO PCT/US2009/051879 patent/WO2010017055A2/en active Application Filing
- 2009-07-27 SM SM20170312T patent/SMT201700312T1/it unknown
- 2009-07-27 EP EP14154664.8A patent/EP2767537B1/en active Active
- 2009-07-27 SG SG2013065719A patent/SG193842A1/en unknown
- 2009-07-27 CN CN201410640197.5A patent/CN104478875B/zh active Active
- 2009-07-27 DK DK09805360.6T patent/DK2326650T3/en active
- 2009-07-27 SI SI200930881T patent/SI2326650T1/sl unknown
- 2009-07-27 EP EP17161893.7A patent/EP3241832A1/en not_active Withdrawn
- 2009-07-27 MX MX2011001328A patent/MX2011001328A/es active IP Right Grant
- 2009-08-04 GB GB0913474A patent/GB2462361A/en not_active Withdrawn
- 2009-08-05 TW TW103106940A patent/TW201422617A/zh unknown
- 2009-08-05 AR ARP090102999A patent/AR072970A1/es active IP Right Grant
- 2009-08-05 TW TW098126400A patent/TWI448464B/zh active
2011
- 2011-02-03 ZA ZA2011/00897A patent/ZA201100897B/en unknown
- 2011-02-03 IL IL211070A patent/IL211070A/en active Protection Beyond IP Right Term
- 2011-03-31 US US13/077,785 patent/US8420650B2/en active Active
- 2011-11-04 HK HK11111926.3A patent/HK1157755A1/xx unknown
2013
- 2013-03-06 US US13/787,496 patent/US8999987B2/en active Active
2014
- 2014-03-28 CY CY20141100240T patent/CY1115022T1/el unknown
2015
- 2015-02-03 HK HK15101138.4A patent/HK1200813A1/xx unknown
- 2015-02-26 US US14/632,825 patent/US9820985B2/en active Active
- 2015-04-30 JP JP2015093417A patent/JP2015157843A/ja active Pending
2017
- 2017-05-31 CY CY20171100578T patent/CY1119218T1/el unknown
- 2017-06-29 HR HRP20170982TT patent/HRP20170982T1/hr unknown
- 2017-07-27 JP JP2017145036A patent/JP2018012698A/ja active Pending
- 2017-09-28 US US15/719,534 patent/US10543209B2/en active Active
2019
- 2019-11-28 NO NO2019042C patent/NO2019042I1/no unknown
- 2019-11-28 CY CY2019044C patent/CY2019044I2/el unknown
- 2019-12-03 FR FR19C1071C patent/FR19C1071I2/fr active Active
- 2019-12-05 LT LTPA2019522C patent/LTC2767537I2/lt unknown
- 2019-12-11 NL NL301021C patent/NL301021I2/nl unknown
- 2019-12-11 LU LU00140C patent/LUC00140I2/fr unknown
- 2019-12-13 US US16/714,474 patent/US10780088B2/en active Active
- 2019-12-19 HU HUS1900053C patent/HUS1900053I1/hu unknown
2020
- 2020-08-21 US US17/000,271 patent/US11364241B2/en active Active

Also Published As

Publication number	Publication date
LUC00140I1 (pt)	2019-12-13
JP5984389B2 (ja)	2016-09-06
CN102171214B (zh)	2015-06-24
NL301021I1 (nl)	2019-12-18
CN103896942A (zh)	2014-07-02
HRP20170982T1 (hr)	2017-09-22
ZA201100897B (en)	2012-06-27
DK2767537T3 (da)	2017-06-19
RU2011108493A (ru)	2012-09-20
EP2767537B1 (en)	2017-04-12
DK2326650T3 (en)	2014-03-10
SI2326650T1 (sl)	2014-04-30
HK1200813A1 (en)	2015-08-14
TW201018688A (en)	2010-05-16
EP2326650A4 (en)	2012-03-21
US20150209357A1 (en)	2015-07-30
JP2015157843A (ja)	2015-09-03
LTPA2019522I1 (lt)	2019-12-27
EP2326650B1 (en)	2014-02-26
AR072970A1 (es)	2010-10-06
TWI448464B (zh)	2014-08-11
WO2010017055A2 (en)	2010-02-11
US20200261454A1 (en)	2020-08-20
CA2732797C (en)	2017-01-03
US20100035883A1 (en)	2010-02-11
PT2767537T (pt)	2017-07-17
NO2019042I1 (no)	2019-11-28
GB2462361A (en)	2010-02-10
RU2514937C2 (ru)	2014-05-10
SG193842A1 (en)	2013-10-30
US8999987B2 (en)	2015-04-07
US9820985B2 (en)	2017-11-21
US8420650B2 (en)	2013-04-16
FR19C1071I1 (pt)	2020-01-17
HK1157755A1 (en)	2012-07-06
WO2010017055A3 (en)	2010-05-27
SG10201809895YA (en)	2018-12-28
CN104478875B (zh)	2017-04-12
US8012976B2 (en)	2011-09-06
PL2326650T3 (pl)	2014-07-31
EP2326650A2 (en)	2011-06-01
LUC00140I2 (pt)	2021-02-12
US10780088B2 (en)	2020-09-22
NZ591166A (en)	2012-11-30
LT2767537T (lt)	2017-08-10
EP2326650B9 (en)	2014-09-10
AU2009279944B2 (en)	2014-09-11
NL301021I2 (nl)	2020-04-14
BRPI0917119B1 (pt)	2021-07-13
ES2466565T3 (es)	2014-06-10
US20210069191A1 (en)	2021-03-11
ES2625817T3 (es)	2017-07-20
US11364241B2 (en)	2022-06-21
EP3241832A1 (en)	2017-11-08
TW201422617A (zh)	2014-06-16
CN104478875A (zh)	2015-04-01
SI2767537T1 (sl)	2017-08-31
CY1119218T1 (el)	2018-02-14
US20110237581A1 (en)	2011-09-29
HUS1900053I1 (hu)	2020-02-28
US10543209B2 (en)	2020-01-28
JP2018012698A (ja)	2018-01-25
CN102171214A (zh)	2011-08-31
AU2009279944A1 (en)	2010-02-11
PT2326650E (pt)	2014-05-06
HUE035295T2 (en)	2018-05-02
KR101846029B1 (ko)	2018-04-06
KR20110040973A (ko)	2011-04-20
PL2767537T3 (pl)	2017-09-29
MX2011001328A (es)	2011-04-04
SMT201700312T1 (it)	2017-09-07
CY1115022T1 (el)	2016-12-14
CY2019044I1 (el)	2020-05-29
IL211070A0 (en)	2011-04-28
US20130190306A1 (en)	2013-07-25
IL211070A (en)	2014-11-30
JP2011530513A (ja)	2011-12-22
CA2732797A1 (en)	2010-02-11
FR19C1071I2 (fr)	2020-10-16
US20180117045A1 (en)	2018-05-03
GB0913474D0 (en)	2009-09-16
EP2767537A1 (en)	2014-08-20
LTC2767537I2 (lt)	2020-11-10
CY2019044I2 (el)	2024-02-16

Publication	Publication Date	Title
BRPI0917119A2 (pt)	2015-11-17	composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
CL2007002649A1 (es)	2008-04-11	Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1009381A2 (pt)	2016-06-21	compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BRPI0816814A2 (pt)	2017-05-16	composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
BRPI0615157A2 (pt)	2016-09-13	composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
IL219529A (en)	2015-06-30	Annotated 4-aminocyclohexane history, medications containing them and the use of history to prepare pain medication
BRPI0912245A2 (pt)	2019-09-24	composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
IL203206A (en)	2015-03-31	2-Amino Derivatives, 4-Amido Quinazoline, Drugs Containing and Using Theirs, and Process for Manufacturing
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0914927A2 (pt)	2017-06-20	composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
CL2007003635A1 (es)	2008-08-22	Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
IL214768A (en)	2016-05-31	Quinazoline derivatives, their pharmaceutical compositions and their use in the treatment of jak-regulated diseases
BRPI0815057A2 (pt)	2015-07-28	Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0907977A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.

Legal Events

Date	Code	Title	Description
2017-05-16	B25A	Requested transfer of rights approved	Owner name: MEDIVATION, INC. (US)
2017-05-30	B25A	Requested transfer of rights approved	Owner name: MEDIVATION TECHNOLOGIES, INC. (US)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-20	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-03-31	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-07-28	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-12-01	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-02-23	B25L	Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled	Owner name: MEDIVATION, INC. (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2421 DE 30/05/2017 POR TER SIDO INDEVIDA.
2021-03-09	B25A	Requested transfer of rights approved	Owner name: MEDIVATION TECHNOLOGIES, INC. (US)
2021-07-13	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.